|23.80||-1.31||-5.22%||Vol 132.96K||1Y Perf 80.47%|
|Apr 16th, 2021 10:33 DELAYED|
|- -%||- -|
|Target Price||56.33||Analyst Rating||Strong Buy 1.00|
|Potential %||132.77||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-68/-63||Value Ranking||★★★+ 54.32|
|Insiders Value % 3/6/12 mo.||-100/-69/-69||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-54/-54||Income Ranking||— -|
|Market Cap||998.62M||Earnings Rating||Sell|
|Price Range Ratio 52W %||49.47||Earnings Date||5th May 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-1.09|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||471.86K|
|Avg. Monthly Volume||1.07M|
|Avg. Quarterly Volume||1.56M|
G1 Therapeutics Inc. (NASDAQ: GTHX) stock closed at 25.11 per share at the end of the most recent trading day (a 1.66% change compared to the prior day closing price) with a volume of 489.72K shares and market capitalization of 998.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 122 people. G1 Therapeutics Inc. CEO is John E. Bailey.
The one-year performance of G1 Therapeutics Inc. stock is 80.47%, while year-to-date (YTD) performance is 39.58%. GTHX stock has a five-year performance of %. Its 52-week range is between 10.81 and 37.07, which gives GTHX stock a 52-week price range ratio of 49.47%
G1 Therapeutics Inc. currently has a PE ratio of -9.60, a price-to-book (PB) ratio of 5.97, a price-to-sale (PS) ratio of 22.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.85%, a ROC of -41.96% and a ROE of -43.58%. The company’s profit margin is -%, its EBITDA margin is -394.50%, and its revenue ttm is $45.29 Million , which makes it $1.08 revenue per share.
Of the last four earnings reports from G1 Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. G1 Therapeutics Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for G1 Therapeutics Inc. is Strong Buy (1), with a target price of $56.33, which is +132.77% compared to the current price. The earnings rating for G1 Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
G1 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
G1 Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.64, ATR14 : 2.05, CCI20 : 68.33, Chaikin Money Flow : 0.22, MACD : -0.28, Money Flow Index : 68.18, ROC : 16.63, RSI : 45.23, STOCH (14,3) : 72.57, STOCH RSI : 1.00, UO : 49.76, Williams %R : -27.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of G1 Therapeutics Inc. in the last 12-months were: Glenn P. Muir (Buy at a value of $675 000), James S. Hanson (Buy at a value of $14 950), Jennifer K. Moses (Option Excercise at a value of $11 160), John E. Bailey (Buy at a value of $204 750), Mark A. Velleca (Option Excercise at a value of $451 829), Mark A. Velleca (Sold 121 040 shares of value $2 727 498 ), Rajesh K. Malik (Option Excercise at a value of $162 038), Rajesh K. Malik (Sold 48 000 shares of value $1 014 882 ), Seth Rudnick (Sold 53 016 shares of value $1 073 379 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.